Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose ticagrelor loading in acute coronary syndrome
ACTRN12613001208796Phase 4Not yet recruiting
- Sponsor
- Peter Larsen
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Peter Larsen. Primary endpoint: Level of platelet inhibition at 2 hours. Planned start Dec 2013; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ACTRN12613001208796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001208796.